ALGS
Aligos Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$6.21
−0.16%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 31.5M | 2.2M | 3.9M | 15.5M | 13.9M |
| Cost of Revenue | 257.0K | 930.0K | — | — | — |
| Gross Profit | 31.3M | 1.3M | 3.9M | 15.5M | 13.9M |
| Operating Expenses | |||||
| R&D Expense | 88.4M | 69.5M | 70.3M | 73.0M | 85.1M |
| SG&A Expense | 21.9M | 20.7M | 22.8M | 30.6M | 26.4M |
| General & Admin Expense | 17.2M | 20.7M | 22.8M | 30.6M | 26.4M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | (930.0K) | — | — | — |
| Total Operating Expenses | 110.3M | 89.2M | 93.1M | 103.7M | 111.5M |
| Cost and Expenses | 110.5M | 90.2M | 93.1M | 103.7M | 111.5M |
| Operating Income (EBIT) | (79.0M) | (88.0M) | (89.2M) | (88.1M) | (97.6M) |
| Non-Operating | |||||
| Interest Income | 2.0M | 2.2M | 1.7M | 1.2M | 1.6M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 2.0M | 2.2M | 1.7M | 1.2M | 1.6M |
| Other Non-Op Income/Expense | 6.2M | 64.1M | (41.7M) | 1.2M | 1.6M |
| Non-Operating Income (excl Interest) | (6.2M) | (64.1M) | 41.7M | (1.2M) | (1.6M) |
| EBT (Pre-Tax Income) | (72.7M) | (23.9M) | (130.9M) | (86.9M) | (95.9M) |
| Income Tax Expense | 3.2M | 314.0K | 331.0K | 795.0K | 106.0K |
| Bottom Line | |||||
| Net Income | (76.0M) | (24.2M) | (131.2M) | (87.7M) | (96.0M) |
| Earnings from Cont. Ops | (76.0M) | (24.2M) | (131.2M) | (87.7M) | (96.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (76.0M) | (24.2M) | (131.2M) | (87.7M) | (96.0M) |
| Per Share | |||||
| Basic EPS | ($7.30) | ($2.45) | ($20.94) | ($3.52) | ($2.25) |
| Diluted EPS | ($7.30) | ($2.45) | ($20.94) | ($3.52) | ($2.25) |
| Revenue Per Share | $3.02 | $0.22 | $0.63 | $0.62 | $0.33 |
| Shares | |||||
| Basic Shares Outstanding | 10.4M | 9.9M | 6.3M | 24.9M | 42.7M |
| Diluted Shares Outstanding | 10.4M | 9.9M | 6.3M | 24.9M | 42.7M |
| Profitability Metrics | |||||
| EBITDA | (71.2M) | (22.9M) | (128.3M) | (83.8M) | (92.3M) |
| D&A | 1.6M | 930.0K | 2.6M | 3.1M | 3.7M |
| EBIT | (72.7M) | (23.9M) | (130.9M) | (86.9M) | (95.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026